StreetInsider.com News Articles

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early,

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

Wed, 21 Oct 2026 10:00:00 -0400

News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.

AMD (AMD) PT Raised to $620 at Susquehanna

Wed, 21 Oct 2026 07:40:10 -0400

Susquehanna analyst Christopher Rolland raised the price target on AMD (NASDAQ: AMD) to $620.00 (from $550.00) while maintaining a Positive rating.

Susquehanna sees modest upside for semiconductor earnings

Wed, 21 Oct 2026 07:17:05 -0400

Investing.com -- Susquehanna analysts said they expect modest upside for third-quarter results and fourth-quarter guidance as semiconductor companies prepare to report earnings. The firm noted that while much of the upside is expected to be linked to artificial intelligence, the broader semiconductor upcycle continues.

Lead times expanded by about two weeks for the second consecutive quarter in the firm's SemiSIGnals data. Pricing actions showed the largest sequential increase of 12% quarter-over-quarter in the third quarter of 2025, with checks suggesting further price increases in the fourth quarter of 2026 and into 2027.